GlassScriptPhysician profile
Alex R Minter
NPI 1265588230
$2,945.07
in general payments reported to CMS, 2019-2025
47 companies · $880 in 2025
The $880 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.61 · 2020: $52.83 · 2021: $193 · 2022: $563 · 2023: $601 · 2024: $587 · 2025: $880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,021 · Education: $47.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,021.11 |
| Education | $47.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $329.21 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $222.61 | 2022-2025 | Opdivo, Opdualag, Augtyro |
| Janssen Biotech, INC. | $203.63 | 2019-2025 | Carvykti, Darzalex, Balversa |
| Gilead Sciences, INC. | $155.22 | 2021-2025 | Trodelvy |
| Amgen INC. | $127.95 | 2020-2022 | |
| Pfizer INC. | $120.61 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $119.18 | 2019-2025 | |
| Valencia Technologies Corporation | $104.31 | 2023 | Ecoin Device Kit |
| Merck Sharp & Dohme LLC | $93.88 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $89.26 | 2024-2025 | Reblozyl, Pomalyst |
| Regeneron Healthcare Solutions, INC. | $85.88 | 2023-2025 | Libtayo |
| Eisai INC. | $77.67 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $69.85 | 2024-2025 | |
| Genentech USA, INC. | $69.39 | 2024-2025 | Polivy, Venclexta, Itovebi |
| Astrazeneca Pharmaceuticals LP | $68.33 | 2021-2025 | Imfinzi, Calquence |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $66.00 | 2021-2022 | |
| Incyte Corporation | $63.29 | 2025 | Monjuvi, Jakafi |
| Daiichi Sankyo INC. | $58.29 | 2024-2025 | Enhertu, Datroway |
| Lilly USA, LLC | $51.90 | 2021-2024 | Verzenio |
| Seagen INC. | $51.73 | 2022-2023 | Adcetris |
| Takeda Pharmaceuticals U.S.A., INC. | $48.27 | 2024-2025 | Ninlaro, Fruzaqla |
| Stemline Therapeutics INC. | $46.54 | 2023-2024 | Orserdu |
| Genmab U.S., INC. | $44.33 | 2023-2024 | Epkinly |
| Array Biopharma INC | $41.42 | 2024-2025 | Lorbrena, Mektovi, Braftovi |
| Pharmacosmos Therapeutics INC. | $40.94 | 2023-2025 | Monoferric |
| Ipsen Biopharmaceuticals, INC | $40.20 | 2021-2025 | Onivyde, Somatuline Depot |
| Beigene USA, INC. | $36.78 | 2022-2023 | Brukinsa |
| Deciphera Pharmaceuticals INC. | $36.12 | 2024-2025 | Qinlock, Romvimza |
| Abbvie INC. | $26.06 | 2024 | |
| Exelixis INC. | $25.61 | 2025 | Cabometyx |
| Aveo Pharmaceuticals, INC. | $24.74 | 2024 | |
| Kyowa Kirin, INC. | $24.45 | 2025 | |
| Beone Medicines USA, INC. | $23.54 | 2025 | Brukinsa |
| Sumitomo Pharma America, INC. | $22.42 | 2025 | Orgovyx |
| Astellas Pharma US INC | $22.29 | 2025 | Vyloy |
| Genzyme Corporation | $22.14 | 2025 | |
| Puma Biotechnology, INC. | $21.14 | 2025 | |
| Adaptive Biotechnologies Corporation | $20.76 | 2025 | Clonoseq |
| Coherus Oncology, INC. | $19.90 | 2025 | Udenyca |
| Adc Therapeutics America, INC. | $18.73 | 2022 | |
| Morphosys, US INC. | $18.69 | 2023 | Monjuvi |
| Glaxosmithkline, LLC. | $18.63 | 2025 | Ojjaara |
| Eusa Pharma (US) LLC | $18.21 | 2019 | |
| Rigel Pharmaceuticals, INC. | $15.95 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Lexicon Pharmaceuticals, INC. | $14.68 | 2020 | |
| Karyopharm Therapeutics INC. | $12.56 | 2022 | |
| Global Blood Therapeutics, INC. | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Minter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.